Dark

Check out our API

DHT
DHT HOLDINGS, INC.
stock NYSE

At Close

Sep 30, 2026 4:00:00 PM EDT

22.58USD+0.691%(+0.16)4,016,380

0.00Bid 0.00Ask 0.00Spread

Pre-market

Sep 30, 2026 9:18:30 AM EDT

22.85USD+1.918%(+0.43)4,932

After-hours

Sep 29, 2026 4:38:30 PM EDT

22.42USD-0.043%(-0.01)0

OverviewOptionsHistoricalExchangesShortsTrends

DHT Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

DHT Specific Mentions

As of Oct 1, 2026 6:28:58 AM EDT (1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

1 day ago • u/No_Construction495 • r/biotech_stocks • bctx_tiny_biotech_waiting_for_trial_results • C

Update
The Phase 2 study patients who were DHT+ lived more than double the length of time compared to those who were
DHT - , 11.3 months vs 4.7 months By saying this is happening in the majority of the current Phase 3 patients, management is heavily implying that most patients on the active drug arm are successfully generating the protective immune response required to extend their lives. Control Arm is of course DHT-.
Unfortunately for the control arm is not doing well. That's 2+2 speculation if management stated they are on track for Dec then the majority must be in the control arm and therefore high likelihood of a.6 HR?
briacell.com/briacell-prese...
•Positive Delayed Type Hypersensitivity
(DTH) may be key predictor of clinical benefit as median overall survival (OS) was significantly (P=0.0001) higher in patients who were DTH+ (11.3 months) vs those who were DTH- (4.7 months).>>

1 day ago • u/No_Construction495 • r/biotech_stocks • bctx_tiny_biotech_waiting_for_trial_results • C

Update
The Phase 2 study patients who were DHT+ lived more than double the length of time compared to those who were
DHT - , 11.3 months vs 4.7 months By saying this is happening in the majority of the current Phase 3 patients, management is heavily implying that most patients on the active drug arm are successfully generating the protective immune response required to extend their lives. Control Arm is of course DHT-.
Unfortunately for the control arm is not doing well. That's 2+2 speculation if management stated they are on track for Dec then the majority must be in the control arm and therefore high likelihood of a.6 HR?
briacell.com/briacell-prese...
•Positive Delayed Type Hypersensitivity
(DTH) may be key predictor of clinical benefit as median overall survival (OS) was significantly (P=0.0001) higher in patients who were DTH+ (11.3 months) vs those who were DTH- (4.7 months).>>

Share